Magnesium taurate and fish oil for prevention of migraine

Medical Hypotheses

Volumn 47, Issue 6, 1996, Pages 461-466

  McCarty, M F ^a  

^a Nutrition 21 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ERGOT ALKALOID; FISH OIL; MAGNESIUM TAURATE; SUMATRIPTAN; TAURINE; UNCLASSIFIED DRUG;

DRUG MECHANISM; HUMAN; MIGRAINE; NERVE CELL EXCITABILITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VASOSPASM;

EID: 0029845303     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(96)90158-9     Document Type: Article

References (94)

1. Welch K M A. Drug therapy of migraine. N Engl J Med 1993; 329: 1476-1483.
2. Greenberg DA. Calcium channel antagonists and the treatment of migraine. Clin Neuropharmacol 1986; 9: 311-328.
3. Solomon G D. Verapamil in migraine prophylaxis - a five-year review. Headache 1989; 29: 425-427.
4. Ludin H-P. The place of calcium antagonists in the prophylactic treatment of migraine. J Cardiovasc Pharmacol 1991; 18 (suppl 8): S17-S19.
5. Sørensen K V. Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand 1988; 78: 346-348.
6. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalagia 1992; 12: 81-84.
7. Drummond P D. Effectiveness of methysergide in relation to clinical features of migraine. Headache 1985; 25: 145-146.
8. O'Neill B P, Mann J D. Aspirin prophylaxis in migraine. Lancet 1978; ii: 1179-1181.
9. Peto R, Gray R, Collins R et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296: 313-316.
10. Buring J E, Peto R, Hennekens C H. Low-dose aspirin for migraine prophylaxis. J Am Med Assoc 1990; 264: 1711-1713.
11. Murphy J J, Heptinstall S, Mitchell J R A. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988; ii: 189-192.
12. Welch K M A, Ellis D J, Keenan P A. Successful migraine prophylaxis with naproxen sodium. Neurology 1985; 35: 1304-1310.
13. Weber R B, Reinmuth O M. The treatment of migraine with propranolol. Neurology 1972; 22: 366-369.
14. Johansson V. Atenolol in migraine prophylaxis: a double-blind crossover multicenter study. Headache 1987; 27: 372-374.
15. Pearce J M S. Is migraine explained by Leao's spreading depression? Lancet 1985; ii: 763-766.
16. Lauritzen M, Olsen T S, Lassen N A, Paulson O B. Changes in regional cerebral blood flow during the course of classic migraine attacks. Ann Neurol 1983; 13: 633-641.
17. Lauritzen M. Cortical spreading depression as a putative migraine mechanism. Trends Neurosci 1987; 10: 8-13.
18. Olesen J, Friberg L, Olsen T S et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990; 28: 791-798.
19. Pollack M A, French J H. Hypothesis: glutamic acid in migraine. Headache 1975; 15: 114-117.
20. Jones R J, Amess J A L, Wachowicz B. Migraine: a platelet disorder. Lancet 1981; ii: 720-723.
21. Hanington E. The platelet and migraine. Headache 1986; 26: 411-415.
22. Joseph R, Welch K M A. The platelet and migraine: a non-specific association. Headache 1987; 27: 375-380.
23. Joseph R, Steiner J T, Poole C J M et al. Thromboxane synthetase inhibition: potential therapy in migraine. Headache 1985; 25: 204-207.
24. Moskowitz M A, Nozaki K, Kraig R P. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 1993; 13: 1167-1177.
25. Buzzi M G, Moskowitz M A. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990; 99: 202-206.
26. Moskowitz M A, Cutrer F M. Sumatriptan: a receptor-targeted treatment for migraine. Annu Rev Med 1993; 44: 145-154.
27. Welch K M A. Migraine. A biobehavioral disorder. Arch Neurol 1987; 44: 323-327.
28. Amery W K. Migraine and cerebral hypoxia: a hypothesis with pharmaco-therapeutic implications. Cephalalgia 1985; suppl 2: 131-133.
29. Swanson D R. Migraine and magnesium: eleven neglected connections. Perspect Biol Med 1988; 31: 526-557.
30. Jain A C, Sethi N C, Babbar P K. A clinical electroencephalographic and trace element study with special reference to zinc, copper and magnesium in serum and cerebrospinal fluid (CSF) in cases of migraine. J Neurol 1985; 232 (suppl): 161.
31. Ramadan N M, Halvorson H, Vande-Linde A et al. Low brain magnesium in migraine. Headache 1989; 29: 416-419.
32. Gallai V, Sarchielli P, Morucci P, Abbritti G. Red blood cell magnesium levels in migraine patients. Cephalalgia 1993; 13: 94-98.
33. Gallai V, Sarchielli P, Morucci P, Abbritte G. Magnesium content of mononuclear blood cells in migraine patients. Headache 1994; 34: 160-165.
34. Facchinetti F, Sances G, Borella P et al. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991; 31: 298-301.
35. Borges L F, Gücer G. Effect of magnesium on epileptic foci. Epilepsia 1978; 19: 81-91.
36. Buck D R, Mahoney A W, Hendricks D G. Preliminary report on the magnesium deficient rat as a model of epilepsy. Lab Anim Sci 1978; 28: 680-685.
37. Mody I, Lambert JDC, Heinemann U. Low extracellular magnesium induces epileptiform activity and spreading depression in rat hippocampal slices. J Neurophysiol 1987; 57: 869-888.
38. Avoli M, Crapeau C, Louvel J et al. Epileptiform activity induced by low extracellular magnesium in the human cortex maintained in vitro. Ann Neurol 1991; 30: 589-596.
39. Bonhaus D W, Laird H, Mimaki T et al. Possible bases for the anti-convulsant action of taurine. In: Kuriyama K, Huxtable R J, Iwata H, eds. Sulfur Amino Acids: Biochemical and Clinical Aspects. New York: Alan R. Liss, 1983: 195-209.
40. Kurachi M, Yoshihara K, Aihara H. Effect of taurine on depolarizations induced by L-glutamate and other excitatory amino acids in the isolated spinal cord of the frog. Jpn J Pharmacol 1983; 33: 1247-1254.
41. Lehmann A, Hagberg H, Hamberger A. A role for taurine in the maintenance of homeostasis in the central nervous system during hyperexcitation? Neurosci Lett 1984; 52: 341-346.
42. Alvarez A, Marcano de Cotte D, Pérez JR et al. Taurine-and penicillin-induced epileptic activity. J Neurosci Res 1984; 11: 187-192.
43. Durelli L, Mutani R. The current status of taurine in epilepsy. Clin Neuropharmacol 1983; 6: 37-48.
44. Kendler B S. Taurine: an overview of its role in preventive medicine. Prev Med 1989; 18: 79-100.
45. Shibata M, Bures J. Techniques for termination of reverberating spreading depression in rats. J Neurophysiol 1975; 38: 158-166.
46. Okamoto K, Kimura H, Sakai Y. Taurine-induced increase of the Cl-conductance of cerebellar Purkinje cell dendrites in vitro. Brain Res 1983; 259: 319-323.
47. Nowak L, Bregestovski P, Ascher P et al. Magnesium gates glutamate-activated channels in mouse central neurones. Nature 1984; 307: 462-465.
48. Finkbeiner S, Stevens C F. Applications of quantitative measurements for assessing glutamate neurotoxicity. Proc Natl Acad Sci 1988; 85: 4071-4074.
49. Rothman S M. Synaptic activity mediates death of hypoxic neurons. Science 1983; 220: 536-537.
50. Sandberg PR, Staines W, McGeer EG. Chronic taurine effects on various neurochemical indices in control and kainic acid-lesioned neostriatum. Brain Res 1979; 161 : 367-370.
51. Fariello R G, Golden G T, Pisa M. Homotaurine (3-aminopropane-sulfonic acid: 3-APS) protects from the convulsant and cytotoxic effects of systemically administered kainic acid. Neurology 1982; 32: 241-245.
52. French E D, Vezzani A, Whetsell W O Jr, Schwarcz R. Anti-excitotoxic effects of taurine in the rat hippocampus in vivo and in vitro. Epilepsia 1985; 26: 506-507.
53. Lehmann A, Hagberg H, Nyström B et al. In vivo regulation of extra-cellular taurine and other neuroactive amino acids in the rabbit hippocampus. In: Oja S S, Ahtee L, Kontro P, Paasonen M K, eds. Taurine: Biological Actions and Clinical Perspectives. New York: Alan R. Liss, 1985: 289-311.
54. Schurr A, Tseng M T, West C A, Rigor B M. Taurine improves the recovery of neuronal function following cerebral hypoxia: an in vitro study. Life Sci 1987; 40: 2059-2066.
55. ++ protect against irreversible damage during CNS ischemia. Stroke 1984; 15: 695-698.
56. Malcangio M, Bartolini A, Ghelardini C et al. Effect of ICV taurine on the impairment of learning, convulsions and death caused by hypoxia. Psychopharmacology 1989; 98: 316-320.
57. Ristori M T, Verdetti J. Effects of taurine on rat aorta in vitro. Fundam Clin Pharmacol 1991; 5: 245-258.
58. Franconi F, Giotti A, Manzini S et al. The effect of taurine on high potassium- and noradrenaline-induced contraction in rabbit ear artery. Br J Pharmacol 1982; 75: 605-612.
59. Nara Y, Yamori Y, Lovenberg W. Effect of dietary taurine on blood pressure in spontaneously hypertensive rats. Biochem Pharmacol 1978; 27: 2689-2692.
60. Inoue A, Takahashi H, Lee L-C et al. Retardation of the development of hypertension in DOCA salt rats by taurine supplement. Cardiovasc Res 1988; 22: 351-358.
61. Nakagawa M, Takeda K, Yoshitomi T et al. Antihypertensive effect of taurine on salt-induced hypertension. In: Huxtable R, Michalk D V, eds. Taurine in Health and Disease. New York: Plenum Press, 1994: 197-206.
62. Meldrum M J, Tu R, Patterson T et al. The effect of taurine on blood pressure, and urinary sodium, potassium and calcium excretion. Huxtable R, Michalk D V, eds. Taurine in Health and Disease. New York: Plenum Press, 1994: 207-215.
63. Yamaguchi A, Kanda S H, Amano H et al. Jpn J Geriatr 1967; 4: 96.
64. Kohashi N, Okabayashi T, Hama J, Katori R. Decreased urinary taurine in essential hypertension. In: Kuriyama K et al, eds. Sulphur Amino Acids: Biochemical and Clinical Aspects. New York: Alan R. Liss, 1983: 73-87.
65. Fujita T, Ando K, Noda H et al. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation 1983; 75: 525-532.
66. Busija D W, Leffler C W. Dilator effects of amino acid neurotransmitters of piglet pial arterioles. Am J Physiol 1989; 257: H1200-H1203.
67. Altura B M, Altura B T, Gebrewold A. Magnesium deficiency and hypertension: correlation between magnesium-deficient diets and microcirculatory changes in situ. Science 1984; 223: 1315-1317.
68. Goldman R S, Finkbeiner S M. Therapeutic use of magnesium sulfate in selected cases of cerebral ischemia and seizure. N Engl J Med 1988; 319: 1224-1225.
69. Sadeh M. Action of magnesium sulfate in the treatment of preeclampsia-eclampsia. Stroke 1989; 20: 1273-1275.
70. Belfort M A, Moise K J Jr. Effect of magnesium sulfate on maternal brain blood flow in preeclampsia: a randomized, placebo-controlled study. Am J Obstet Gynecol 1992; 167: 661-666.
71. Hayes K C, Pronczuk A, Addesa A E, Stephan Z F. Taurine modulates platelet aggregation in cats and humans. Am J Clin Nutr 1989; 49: 1121-1126.
72. Franconi F, Miceli M, Bennardini F et al. Taurine potentiates the antiaggregatory action of aspirin and indomethacin. In: Lombardini J B et al, eds. Taurine. New York: Plenum Press, 1992: 181-186.
73. Atahanov S E, Elizarova E P. Modulation of receptor-dependent increase of calcium ions in human platelets by taurine. Arzneimittelforschung 1992; 42: 1311-1313.
74. 2 synthesis in the rat. Prostaglandins 1987; 33: 17-24.
75. Hughes A, Tonks R S. Platelets, magnesium and myocardial infarction. Lancet 1965; i: 1044-1046.
76. Szelenyi I, Rigo J, Ahmed B O, Sos J. The role of magnesium in blood coagulation. Thromb Diath Haemorrh 1967; 18: 626-633.
77. Nadler J L, Goodson S, Rude R K. Evidence that prostacyclin mediates the vascular action of magnesium in humans. Hypertension 1987; 9: 379-383.
78. Appenzeller O. Pathogenesis of migraine. Headache 1991; 75: 763-789.
79. Färkkilä M, Palo J, Saijonmaa O, Fyhrquist F. Raised plasma endothelin during acute migraine attack. Cephalalgia 1992; 12: 383-384.
80. Geib K R, Jester I, Falke W et al. The effect of a taurine-containing drink on performance in 10 endurance athletes. Amino Acids 1994; 7: 45-56.
81. Kenny D, Warltier D C, Pleuss J A et al. Effect of omega-3 fatty acids on the vascular response to angiotensin in normotensive men. Am J Cardiol 1992; 70: 1347-1352.
82. Chin J P F, Gust A P, Nestel P J, Dart A M. Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans. Hypertension 1993; 21: 22-28.
83. Knapp H R, Fitzgerald G A. The antihypertensive effects of fish oil: a controlled study of polyunsaturated fatty acid supplements in essential hypertension. N Engl J Med 1989; 320: 1037-1043.
84. Bønaa K H, Bjerve K S, Straume B et al. Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension. N Engl J Med 1990; 322: 795-801.
85. Hay C R, Durber A P, Saynor R. Effect of fist oil on platelet kinetics in patients with ischaemic heart disease. Lancet 1982; i: 1269-1270.
86. Knapp H R, Reilly A I, Alessandrini P, FitzGerald G A. In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. N Engl J Med 1986; 314: 937-947.
87. Goodnight S H, Cairns J A, Fisher M, FitzGerald G A. Assessment of the therapeutic use of n-3 fatty acids in vascular disease and thrombosis. Chest 1992; 102: 374S-384S.
88. Black K L, Culp B, Madison D et al. The protective effects of dietary fish oil on focal cerebral infarction. Prostaglandin Med 1979; 5: 247-252.
89. McCarren T, Hitzemann R, Smith R et al. Amelioration of severe migraine by fish oil (ω-3) fatty acids. Am J Clin Nutr 1985; 41: 874.
90. Glueck C J, McCarren T, Hitzmann R et al. Amelioration of severe migraine with omega-3 fatty acids: a double-blind, placebo-controlled clinical trial. Am J Clin Nutr 1986; 43: 70.
91. Horrobin D F. Hypothesis: prostaglandins and migraine. Headache 1977; 17: 113-117.
92. Puig-Parellada P, Planas J M, Giménez J, Obach J. Migraine: implication of arachidonic acid metabolites. Prost Leukot Essent Fatty Acids 1993; 49: 537-547.
93. McCarty M F. Up-regulation of intracellular signalling pathways may play a central pathogenic role in hypertension, atherogenesis, insulin resistance, and cancer promotion - the 'PKC syndrome'. Med Hypotheses 1996; 46: 191-221.
94. McCarty M F. Complementary vascular-protective actions of magnesium and taurine - a rationale for magnesium taurate. Med Hypotheses 1996; 46: 89-100.